NCT07085611

Neutralizing Power of Serum Antibodies - 2

Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Centre Hospitalier Régional d'Orléans · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.

Detailed description

This is a monocentric, longitudinal, descriptive study aiming to measure and describe the evolution of the humoral immune response (serum and nasal) to SARS-CoV-2 and MPXV, following any vaccination or administration of monoclonal antibodies. Samples are collected over a maximum 60-month period per participant to assess the durability of neutralizing activity.

Conditions

• COVID-19
• SARS-CoV-2 Viraemia
• Monkey Pox
• Vaccination
• Serum
• Mucosal Immunity

Interventions

Type	Name	Description
OTHER	Sample collection (blood and optional nasal swab)	Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur

Timeline

• Start date: 2025-08-22
• Primary completion: 2030-08-22
• Completion: 2035-07-11
• First posted: 2025-07-25
• Last updated: 2025-12-19

Locations

1 site across 1 country: France